{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:14:23Z","timestamp":1778210063711,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004351","name":"Sultan Qaboos University","doi-asserted-by":"publisher","award":["IG\/MED\/PHAR\/23\/01"],"award-info":[{"award-number":["IG\/MED\/PHAR\/23\/01"]}],"id":[{"id":"10.13039\/501100004351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004351","name":"Sultan Qaboos University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-05079-1","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:27:37Z","timestamp":1770467257000},"page":"10643-10654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of sacubitril\/valsartan compared to valsartan in experimentally induced chronic kidney disease"],"prefix":"10.1007","volume":"399","author":[{"given":"Raya","family":"Al Maskari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asem","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadarsini","family":"Manoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousuf M.","family":"Al Suleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"5079_CR1","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1038\/s41598-020-69810-5","volume":"10","author":"GA Abdel-Latif","year":"2020","unstructured":"Abdel-Latif GA, Elwahab AHA, Hasan RA, ElMongy NF, Ramzy MM, Louka ML, Schaalan MF (2020) A novel protective role of sacubitril\/valsartan in cyclophosphamide-induced lung injury in rats: impact of miRNA-150-3p on NF-\u03baB\/MAPK signaling trajectories. Sci Rep 10:13045. https:\/\/doi.org\/10.1038\/s41598-020-69810-5","journal-title":"Sci Rep"},{"key":"5079_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biology14020161","volume":"14","author":"AM Abdelrahman","year":"2025","unstructured":"Abdelrahman AM, Al Maskari R, Ali H, Manoj P, Al Suleimani Y (2025) Effect of riociguat on adenine-induced chronic kidney disease in rats. Biol 14:161. https:\/\/doi.org\/10.3390\/biology14020161","journal-title":"Biol"},{"key":"5079_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s43032-023-01410-w","volume":"31","author":"S Atta","year":"2024","unstructured":"Atta S, Mekky R, Ibrahim M, Abdallah MM, Elbaz MAH, Radwan E (2024) Increased expression of neprilysin is associated with inflammation in preeclampsia. Reprod Sci 31:1385\u20131390. https:\/\/doi.org\/10.1007\/s43032-023-01410-w","journal-title":"Reprod Sci"},{"key":"5079_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40262-017-0558-9","volume":"57","author":"S Ayalasomayajula","year":"2018","unstructured":"Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G (2018) Erratum to: Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor\u2013neprilysin inhibitor. Clin Pharmacokinet 57:105\u2013123. https:\/\/doi.org\/10.1007\/s40262-017-0558-9","journal-title":"Clin Pharmacokinet"},{"key":"5079_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031288","volume":"23","author":"OM Belali","year":"2022","unstructured":"Belali OM, Ahmed MM, Mohany M, Belali TM, Alotaibi MM, Al-Hoshani A, Al-Rejaie SS (2022) LCZ696 protects against diabetic cardiomyopathy-induced myocardial inflammation, ER stress, and apoptosis through inhibiting AGEs\/NF-\u03baB and PERK\/CHOP signaling pathways. Int J Mol Sci 23:1288. https:\/\/doi.org\/10.3390\/ijms23031288","journal-title":"Int J Mol Sci"},{"key":"5079_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","volume":"38","author":"M B\u00f6hm","year":"2017","unstructured":"B\u00f6hm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38:1132\u20131143. https:\/\/doi.org\/10.1093\/eurheartj\/ehw570","journal-title":"Eur Heart J"},{"key":"5079_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biom14111393","volume":"14","author":"A Caturano","year":"2024","unstructured":"Caturano A, Galiero R, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Di Lorenzo G, Sardu C, Russo V, Vetrano E, Monda M, Marfella R, Rinaldi L, Sasso FC (2024) The dual burden: exploring cardiovascular complications in chronic kidney disease. Biomolecules 14:1393. https:\/\/doi.org\/10.3390\/biom14111393","journal-title":"Biomolecules"},{"key":"5079_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286903","volume":"18","author":"J Ding","year":"2023","unstructured":"Ding J, Cui S, Li SY, Cui LY, Nan QY, Lin XJ, Xuan MY, Jin J, Piao SG, Jiang YJ, Zheng HL, Jin JZ, Chung BH, Yang CW, Cui JH, Li C (2023) The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1\/JNK\/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. PLoS ONE 18:e0286903. https:\/\/doi.org\/10.1371\/journal.pone.0286903","journal-title":"PLoS ONE"},{"key":"5079_CR9","doi-asserted-by":"publisher","first-page":"e33984","DOI":"10.1097\/MD.0000000000033984","volume":"102","author":"C Elendu","year":"2023","unstructured":"Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, Meribole ES, Lawal SO, Okenwa CJ, Okafor GC, Umeh ED, Mutalib OO, Opashola KA, Fatoye JO, Awotoye TI, Tobih-Ojeanelo JI, Ramon-Yusuf HI, Olanrewaju A, Afuh RN, Adenikinju J, Amosu O, Yusuf A (2023) Comprehensive review of current management guidelines of chronic kidney disease. Med (Baltimore) 102:e33984. https:\/\/doi.org\/10.1097\/MD.0000000000033984","journal-title":"Med (Baltimore)"},{"key":"5079_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C, Malik C, Hradsky A, Adu D, Bavanandan S, Cusumano A, Sola L, Ulasi I, Jha V (2024) Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20:473\u2013485. https:\/\/doi.org\/10.1038\/s41581-024-00820-6","journal-title":"Nat Rev Nephrol"},{"key":"5079_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000507327","volume":"145","author":"Q Geng","year":"2020","unstructured":"Geng Q, Yan R, Wang Z, Hou F (2020) Effects of LCZ696 (sacubitril\/valsartan) on blood pressure in patients with hypertension: a meta-analysis of randomized controlled trials. Cardiology 145:589\u2013598. https:\/\/doi.org\/10.1159\/000507327","journal-title":"Cardiology"},{"key":"5079_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","volume":"1851","author":"PT Hawkins","year":"2015","unstructured":"Hawkins PT, Stephens LR (2015) Pi3k signalling in inflammation. Biochim Biophys Acta Mol Cell Biol Lipids 1851:882\u2013897. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.006","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"5079_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C (2018) Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138:1505\u20131514. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034818","journal-title":"Circulation"},{"key":"5079_CR14","first-page":"5473","volume":"9","author":"W Jing","year":"2017","unstructured":"Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, Moradi H (2017) LCZ696 (sacubitril\/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Transl Res 9:5473\u20135484","journal-title":"Am J Transl Res"},{"key":"5079_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ajh\/hpaf028","volume":"38","author":"S Kinguchi","year":"2025","unstructured":"Kinguchi S, Ishiga K, Wakui H, Azushima K, Kanaoka T, Kobayashi Y, Haze T, Hirawa N, Tamura K (2025) Switching from ARBs to sacubitril\/valsartan safely improves 24-hour ambulatory blood pressure in patients with advanced chronic kidney disease. Am J Hypertens 38:380\u2013388. https:\/\/doi.org\/10.1093\/ajh\/hpaf028","journal-title":"Am J Hypertens"},{"key":"5079_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.330","volume":"4","author":"W Lai","year":"2023","unstructured":"Lai W, Huang R, Wang B, Shi M, Guo F, Li L, Ren Q, Tao S, Fu P, Ma L (2023) Novel aspect of neprilysin in kidney fibrosis via ACSL4-mediated ferroptosis of tubular epithelial cells. MedComm 4:e330. https:\/\/doi.org\/10.1002\/mco2.330","journal-title":"MedComm"},{"key":"5079_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32862","volume":"7","author":"J Li","year":"2024","unstructured":"Li J, Liu Q, Lian X, Yang S, Lian R, Li W, Yu J, Huang F, Chen W, He F, Chen W (2024) Kidney outcomes following angiotensin receptor-neprilysin inhibitor vs angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker therapy for thrombotic microangiopathy. JAMA Netw Open 7:e2432862. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.32862","journal-title":"JAMA Netw Open"},{"issue":"1","key":"5079_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ajh\/hpaf143","volume":"39","author":"Z Lv","year":"2025","unstructured":"Lv Z, Dai W, Rong S, Du J (2025) Effect of sacubitril\u2013valsartan on transcriptomic changes in lung tissue of spontaneously hypertensive rats: a multi-omics study based on RNA-Seq transcriptome analysis. Am J Hypertens 39(1):171. https:\/\/doi.org\/10.1093\/ajh\/hpaf143","journal-title":"Am J Hypertens"},{"key":"5079_CR19","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1055\/s-0040-1705138","volume":"4","author":"C Makhloufi","year":"2020","unstructured":"Makhloufi C, Crescence L, Darbousset R, McKay N, Massy ZA, Dubois C, Panicot-Dubois L, Burtey S, Poitevin S (2020) Assessment of thrombotic and bleeding tendency in two mouse models of chronic kidney disease: adenine-diet and 5\/6th nephrectomy. TH Open Companion J Thromb Haemost 4:e66\u2013e76. https:\/\/doi.org\/10.1055\/s-0040-1705138","journal-title":"TH Open Companion J Thromb Haemost"},{"key":"5079_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112863","volume":"10","author":"M Mohany","year":"2022","unstructured":"Mohany M, Ahmed MM, Al-Rejaie SS (2022) The role of NF-\u03baB and Bax\/Bcl-2\/Caspase-3 signaling pathways in the protective effects of sacubitril\/valsartan (Entresto) against HFD\/STZ-induced diabetic kidney disease. Biomedicines 10:2863. https:\/\/doi.org\/10.3390\/biomedicines10112863","journal-title":"Biomedicines"},{"key":"5079_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jch.70089","volume":"27","author":"M Murakoshi","year":"2025","unstructured":"Murakoshi M, Kobayashi T, Kihara M, Ueda S, Suzuki Y, Gohda T (2025) Effects of sacubitril\/valsartan on blood pressure and proteinuria in hypertensive patients with chronic kidney disease. J Clin Hypertens 27:e70089. https:\/\/doi.org\/10.1111\/jch.70089","journal-title":"J Clin Hypertens"},{"key":"5079_CR22","doi-asserted-by":"publisher","first-page":"F1133","DOI":"10.1152\/ajprenal.00614.2020","volume":"320","author":"K Myakala","year":"2021","unstructured":"Myakala K, Jones BA, Wang XX, Levi M (2021) Sacubitril\/valsartan treatment has differential effects in modulating diabetic kidney disease in db\/db mice and KKAy mice compared with valsartan treatment. Am J Physiol Ren Physiol 320:F1133\u2013F1151. https:\/\/doi.org\/10.1152\/ajprenal.00614.2020","journal-title":"Am J Physiol Ren Physiol"},{"key":"5079_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ejhf.2450","volume":"24","author":"A Peikert","year":"2022","unstructured":"Peikert A, Vaduganathan M, Causland FM, Claggett BL, Chatur S, Packer M, Pfeffer MA, Zannad F, Lefkowitz MP, Pieske B, D\u00fcngen H-D, McMurray JJ, Solomon SD (2022) Effects of sacubitril\/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. Eur J Heart Fail 24:794. https:\/\/doi.org\/10.1002\/ejhf.2450","journal-title":"Eur J Heart Fail"},{"key":"5079_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","volume":"7","author":"R Pontremoli","year":"2021","unstructured":"Pontremoli R, Borghi C, Perrone Filardi P (2021) Renal protection in chronic heart failure: focus on sacubitril\/valsartan. Eur Heart J Cardiovasc Pharmacother 7:445\u2013452. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab030","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"5079_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-311295","author":"JSS Singh","year":"2017","unstructured":"Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC (2017) Sacubitril\/valsartan: beyond natriuretic peptides. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2017-311295","journal-title":"Heart"},{"key":"5079_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.kint.2021.10.025","volume":"101","author":"J Soppert","year":"2022","unstructured":"Soppert J, Frisch J, Wirth J, Hemmers C, Boor P, Kramann R, Vondenhoff S, Moellmann J, Lehrke M, Hohl M, Van der Vorst EPC, Werner C, Speer T, Maack C, Marx N, Jankowski J, Roma LP, Noels H (2022) A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int 101:256\u2013273. https:\/\/doi.org\/10.1016\/j.kint.2021.10.025","journal-title":"Kidney Int"},{"key":"5079_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","volume":"24","author":"Y Suematsu","year":"2018","unstructured":"Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H (2018) LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Card Fail 24:266\u2013275. https:\/\/doi.org\/10.1016\/j.cardfail.2017.12.010","journal-title":"J Card Fail"},{"key":"5079_CR28","doi-asserted-by":"publisher","first-page":"oead098","DOI":"10.1093\/ehjopen\/oead098","volume":"3","author":"S Tsukamoto","year":"2023","unstructured":"Tsukamoto S, Wakui H, Uehara T, Shiba Y, Azushima K, Abe E, Tanaka S, Taguchi S, Hirota K, Urate S, Suzuki T, Yamada T, Kinguchi S, Yamashita A, Tamura K (2023) Combination of sacubitril\/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome. Eur Heart J Open 3:oead098. https:\/\/doi.org\/10.1093\/ehjopen\/oead098","journal-title":"Eur Heart J Open"},{"key":"5079_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1755-5922.2009.00085.x","volume":"27","author":"N Tzemos","year":"2009","unstructured":"Tzemos N, Lim PO, MacDonald TM (2009) Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther 27:151\u2013158. https:\/\/doi.org\/10.1111\/j.1755-5922.2009.00085.x","journal-title":"Cardiovasc Ther"},{"key":"5079_CR30","doi-asserted-by":"publisher","first-page":"e00336","DOI":"10.1002\/prp2.336","volume":"5","author":"K Ushijima","year":"2017","unstructured":"Ushijima K, Ando H, Arakawa Y, Aizawa K, Suzuki C, Shimada K, Tsuruoka S, Fujimura A (2017) Prevention against renal damage in rats with subtotal nephrectomy by sacubitril\/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor. Pharmacol Res Perspect 5:e00336. https:\/\/doi.org\/10.1002\/prp2.336","journal-title":"Pharmacol Res Perspect"},{"key":"5079_CR31","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.cjca.2024.02.027","volume":"40","author":"N Vendeville","year":"2024","unstructured":"Vendeville N, Lepage MA, Festa MC, Mavrakanas TA (2024) Clinical outcomes of renin-angiotensin-aldosterone blockade in patients with advanced chronic kidney disease: a systematic review and meta-analysis. Can J Cardiol 40:1718\u20131728. https:\/\/doi.org\/10.1016\/j.cjca.2024.02.027","journal-title":"Can J Cardiol"},{"key":"5079_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02627-6","volume":"24","author":"W Wei","year":"2025","unstructured":"Wei W, Xu G, Gao J, Wang G, Wang Y, Li C, Zheng J, Lu H, Lu Y, Wang K, Xu H, Wang C, Pan X (2025) Sacubitril\/valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs. Cardiovasc Diabetol 24:89. https:\/\/doi.org\/10.1186\/s12933-025-02627-6","journal-title":"Cardiovasc Diabetol"},{"key":"5079_CR33","unstructured":"Wong SS, Sun NN, Fastje CD, Witten ML, Lantz RC, Lu B, Sherrill DL, Gerard CJ, Burgess JL (2011) HEI Health Review Committee. Role of neprilysin in airway inflammation induced by diesel exhaust emissions. Res Rep Health Eff Inst (159):3\u201340"},{"key":"5079_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1152\/advan.00177.2016","volume":"41","author":"PCY Wong","year":"2017","unstructured":"Wong PCY, Guo J, Zhang A (2017) The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ 41:179\u2013185. https:\/\/doi.org\/10.1152\/advan.00177.2016","journal-title":"Adv Physiol Educ"},{"key":"5079_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1501407","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang X, Hu C, Tian E, Shen Y, Liu W, Li J (2024) Comprehensive review on neprilysin (NEP) inhibitors: design, structure\u2013activity relationships, and clinical applications. Front Pharmacol 15:1501407. https:\/\/doi.org\/10.3389\/fphar.2024.1501407","journal-title":"Front Pharmacol"},{"key":"5079_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11255-023-03599-w","volume":"56","author":"W Zhou","year":"2024","unstructured":"Zhou W, Yang X, Jin J, Cheng M, Li Y, Bai Y, Xu J (2024) The efficacy and safety of sacubitril\/valsartan in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 56:181\u2013190. https:\/\/doi.org\/10.1007\/s11255-023-03599-w","journal-title":"Int Urol Nephrol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05079-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05079-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:44:14Z","timestamp":1778208254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05079-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5079"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05079-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}